Peter Barton Hutt, Angels for Change, and City of Hope to Receive 2026 Innovations in Regulatory Science & Policy Awards
Reagan-Udall Foundation for the FDA awards celebration marks 10 years on December 8
(October 21, 2026) – The Reagan-Udall Foundation for the FDA will recognize the late Peter Barton Hutt, Angels for Change, and City of Hope at its 10th annual Innovations in Regulatory Science & Policy Awards on December 8, 2026. The awards honor contributions to regulatory science and public health in three categories: Leadership, Innovation, and Advocacy/Policy.
“For a decade, these awards have celebrated individuals and organizations whose leadership, innovation, and advocacy translate scientific progress into better health,” said Adrian F. Hernandez, MD, MHS, Chair of the Foundation’s Board of Directors. “This year’s honorees embody that mission—shaping sound policy, advancing research and care, and championing solutions grounded in patients’ needs.”
The 2026 Leadership Award will be presented posthumously to Peter Barton Hutt, whose decades of service helped shape modern food and drug law. As Chief Counsel of the U.S. Food and Drug Administration from 1971 to 1975, Hutt helped advance the agency’s approach to regulation. His contributions continued through his legal scholarship and more than three decades of teaching food and drug law at Harvard Law School. The Foundation will celebrate Hutt’s lasting influence on regulatory policy and the generations of practitioners he educated and mentored.
The 2026 Innovation Honoree is City of Hope. The award recognizes its innovative, integrated approach to translating scientific discovery into new therapies, expanding access to clinical trials, and accelerating advances in cancer research and care. It also recognizes the culture of innovation forged under CEO Robert Stone’s leadership, where researchers and clinicians are empowered to integrate research and care.
The 2026 Advocacy/Policy Honoree is Angels for Change, a nonprofit organization dedicated to ending drug shortages through advocacy, awareness, and a more resilient pharmaceutical supply chain. The organization advocates for patients facing shortages of lifesaving medicines and builds relationships with patients and supply chain partners to advance solutions. Its work brings patients’ experiences to the forefront of efforts to improve reliable access to treatment.
“We are excited to recognize the work and impact of our 2026 honorees,” says Foundation CEO Susan C. Winckler, RPh, Esq. “We’re also excited to celebrate ten years of honoring those who turn evidence, experience, and bold ideas into action that advances a regulatory system that better serves patients and the public.”